£10m funding for children's gender research including NHS puberty blocker trial
Plans for a trial were announced last year following the publication of the Cass Review which concluded the quality of studies claiming to show beneficial effects of such medication for children and young people with gender dysphoria was 'poor'.
An NHS-commissioned study, to last until 2031, has now been confirmed by the National Institute for Health and Care Research (NIHR), to be carried out by a team of researchers led by King's College London on a contract worth £10,694,902.24.
Baroness Hilary Cass, who authored the 2024 report in her name, said the research aims to 'fill some of the gaps in our knowledge about the outcomes of different interventions and address some of the uncertainty about the impacts and efficacy of puberty suppressing hormones'.
The puberty blocker trial will form part of the four-part wider Pathways study.
It will see young people, who have the agreement of their parents and NHS gender services, given puberty suppressing hormones (gonadotropin releasing hormone analogues or GnRHa) while having their physical, social and emotional well-being monitored across two years.
Other parts of the overall study will involve tracking the well-being of children, including those not on the puberty blocker trial, attending NHS gender clinics.
The research will also monitor whether puberty blockers affect young people's thinking and brain development, using various activities and brain scans.
Researchers will speak to young people about their experiences of living with gender incongruence and of the care they get, as well as obtaining the views of parents and staff.
The first patients had been expected to be recruited to the puberty blocker trial this spring but the NHS has noted this will be subject to strict ethical and regulatory approval.
Professor James Palmer, who is the NHS national medical director for specialised services, said: 'This suite of research will examine the evidence for a range of clinical care, including the use of puberty suppressing hormones, following advice from the Cass Review.
'Independent researchers led by King's College London will now progress this joint NHS and NIHR project, which will be subject to strict ethical and regulatory approval and follow stringent safeguards in scientific research.
'In the meantime, the NHS continues to expand and improve services for children and young people with gender dysphoria and incongruence, in line with recommendations from the Cass Review.'
Baroness Cass added: 'Access to the study will be through the new NHS children and young people's gender services where a multi-disciplinary team approach will be taken to identify those children who, with the consent of their parents, may be deemed clinically suitable for consideration of puberty suppressing hormones through the study.
'The children participating in the study will also continue to receive comprehensive psychosocial support.'
Puberty blockers are not prescribed on the NHS to children for the treatment of gender dysphoria, with a ban last year being made permanent in December with the agreement of devolved governments across the UK.
The ban sought to close a loophole on the sale and supply of puberty blockers through private prescriptions for under-18s after the Commission on Human Medicines (CHM) published independent expert advice that there is 'currently an unacceptable safety risk in the continued prescription of puberty blockers to children'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
35 minutes ago
- Times
Obese to get soups and shakes diet instead of weight-loss jabs
Low-calorie soups and shakes are to be prescribed to thousands of overweight people in Scotland in an attempt to reduce their dependence on expensive weight-loss drugs and provide longer-lasting health benefits. From January, 3,000 patients who have been newly diagnosed with type 2 diabetes will be recruited for a clinical trial. About 300,000 Scots live with type 2 diabetes, a condition commonly linked to obesity, in which badly regulated blood sugar levels can increase the risk of heart disease, kidney disease, strokes or nerve conditions. About 10,000 of them are being treated with weight-loss drugs such as Ozempic, Wegovy and Mounjaro, with injections costing the NHS £3,000 a year. The estimated annual bill of £30 million is expected to rise as manufacturers raise prices. NHS chiefs believe that not only will the soups and shakes plan be less expensive, it will also bring longer-term health benefits. In the Total Diet Replacement (TDR) plan, to be rolled out over three years, patients who have recently been diagnosed with type 2 diabetes and are deemed eligible will be given low-calorie substitutes for their breakfast, lunch and dinner. The replacement meals, containing a maximum of 900 calories a day, will be delivered to patients for between three and five months. • What to do now Mounjaro's hiking its prices, by an obesity expert After this initial period, normal food will be reintroduced, but with guidance given on healthy meals through online consultations and an app. The ambition is for patients to lose up to 10 per cent of their body weight over a year. Doctors are also optimistic that up to 40 per cent of the trial participants will achieve remission from type 2 diabetes within a year. There are fears that the weight lost through injections — which work by suppressing the appetite — may last only as long as the patient is taking the drug. By contrast, the effects of diet changes should prove more long-lasting and cost effective, NHS officials believe. The TDR scheme is set to cost £5.6 million for 3,000 patients, a one-off cost of about £1,866 per person. Doctors hope the plan will help patients to fundamentally alter their diet and lifestyle. A spokesman for the Scottish government said: 'We anticipate that around 35 to 40 per cent will achieve remission from type 2 diabetes at the end of their first year on the programme, with a majority of patients benefiting from a clinically significant average weight loss of 10 per cent.' This would lead to reductions in blood pressure and contribute to a reduced risk of cardiovascular disease. He added: 'We will measure impact by the number of patients recruited into this programme, the number who achieve remission and the number with clinically significant weight loss.'
The Independent
4 hours ago
- The Independent
Pricing people out of using Mounjaro would be bad news for the NHS
There were scenes of shock in pharmacies across the country when a notice from pharmaceutical giant Eli Lilly hit inboxes out of nowhere last week. The wholesale price of their popular weight-loss drug Mounjaro, administered via jabs, was going to more than double from the start of September. While Eli Lilly has struck an, as yet secret, deal with the NHS, this massive increase will hit the vast majority of patients who are prescribed Mounjaro privately. More than a million Britons are estimated to already be taking Mounjaro, and scores more are interested in using it to start their weight-loss journey. So, when the news of this massive price hike went public, it wasn't only pharmacists who were worried and disappointed. The first message to concerned patients is don't panic and don't stop taking your medication; your local pharmacy is ready and willing to talk you through the options going forward. There are alternatives to Mounjaro that, for now at least, remain cheaper. They may be right for you, but it is essential that you get professional advice before you do anything, and your neighbourhood pharmacist is best placed and most on hand to give that advice. The consequences of this unprecedented price hike won't just hit patients; they will also hit the pharmacies on Britain's high streets. The finances of the whole pharmacy sector are already in a state of crisis after years of underfunding. The price hike for Mounjaro will put it under more financial strain. Unless the government steps in and offers the sector a fairer funding settlement for our NHS work, then, inevitably, we are going to see more pharmacies close and more communities robbed of the vital service on their street corner. If the government really wants pharmacies to be the 'front door' of their Neighbourhood Health Service, then it needs to act now. We call on the other weight-loss manufacturers to hold their nerve and hold their prices. The British market for weight-loss jabs was only set to grow, but it will only achieve that growth if treatment remains affordable to the average patient. There is a real danger that patients priced out of Mounjaro, but anxious to maintain treatment, turn to sourcing replacements online. If other manufacturers follow suit and up their prices, that danger will only grow. In their desperation, patients could well end up sourcing counterfeit jabs online, which are completely unregulated and potentially extremely harmful. At the click of a mouse, patients can find themselves buying jabs that they have no idea what they contain, or if they were manufactured in safe conditions, no matter what picture the unscrupulous sites use to tempt them in. We are urging patients to be extremely cautious and vigilant when looking to buy weight loss medication online. If it looks too good to be true, it almost certainly is. Again, talk to your trained and regulated community pharmacy, which is there to help. There is a real risk it won't end here. Although the companies would deny it, tariffs and the noise from the White House would seem to be hitting this side of the Atlantic. British patients must not become pawns in a wider dispute about the costs of medicines arising from President Trump's recent letter to the US drug manufacturers. For now, it seems that weight-loss jabs prescribed privately are the easy win for the pharma giants, but we are concerned that more companies may increase the prices of more medicines as a result of tariffs. Any increases in wholesale prices, even for those drugs prescribed by the NHS, will impact the sustainability of the sector. The Mounjaro price hike came out of the blue. It could prove just the start. Exploding prices for pharmaceuticals risks a genuine and rapid crisis. Ministers need to urgently develop contingency plans; otherwise, we risk the system that keeps vital medicines flowing to patients entering an unprecedented era of uncertainty.
Daily Record
5 hours ago
- Daily Record
GP explains difference between ‘chronic fatigue' signs and normal burnout
Chronic Fatigue Syndrome symptoms and general burnout can be hard to tell apart, but one GP is highlighting the difference Chronic Fatigue Syndrome (CFS), also known as myalgic encephalomyelitis, is a complex and long-term condition that can severely impact a person's daily life. However, it can be hard to diagnose as the symptoms often overlap and mimic a range of other issues like general burnout or sleep disorders. There's no single way of treating CFS, it's all individually tailored to each person's symptoms according to the NHS so getting a speedy diagnosis is vital to address the issues impacting your daily life. Dr Donald Grant, GP and Senior Clinical Advisor at The Independent Pharmacy, highlighted the few signs that set CFS apart. He said: 'While burnout and CFS share some common symptoms, they can also be incredibly different. Understanding the contrasts can allow people to identify chronic fatigue more effectively. 'Typically, feelings of burnout are brought on through excessive stress, almost always tied to a particular event such as work. Burnout can be treated through rest and addressing the issues that cause overwhelming stress. 'On the other hand, CFS is a long-term condition that isn't relieved through sleep, recovery or addressing potential stressors. Instead, the body can feel like it's run a marathon, even after the smallest of tasks. While burnout is generally psychological, CFS can impact the body on a physical level.' Certain factors can also heighten your chances of developing CFS or make the symptoms worse, including the menopause, mental health problems, long Covid and other viral infections. However, the main culprit is typically sleep troubles such as insomnia or being unable to maintain a regular sleep pattern that delivers seven to nine hours of rest nightly. The GP continued: 'Other signs of CFS include changes to cognitive function such as difficulty with memory, concentration or general brain fog. 'It's also common for people with CFS to feel worn out after completing simple tasks, while also experiencing joint and muscle pain, without necessarily putting their bodies through any physical exertion.' Plenty of people might encounter one or two of these symptoms occasionally, or even struggle with burnout and general exhaustion. However, the GP encouraged people to discuss these concerns openly with their doctor as there's currently no specific method to diagnose CFS and highlighting your symptoms can result in a swifter and more precise diagnosis. He continued: 'GPs will generally ask about lifestyle habits and potential stressors while assessing prior medical history to identify potential causes of decreasing energy levels. Like the diagnosis process, there's no specific way to treat CFS. 'Instead, doctors will trial a few different approaches. This includes cognitive behaviour therapy (CBT) and incorporating methods for energy management into people's daily routines. 'Also, as CFS can impact sleep or physical pain, a GP might prescribe medications that can target and lower the intensity of these symptoms. Overall, I believe CFS can be complicated to identify, for both medical professionals and potential sufferers. However, by understanding the tell-tale signs and how it differs from burnout or general tiredness, spotting CFS can be made so much easier.'
